Jupiter Asset Management Ltd. Purchases 156,952 Shares of Pfizer Inc. $PFE

Jupiter Asset Management Ltd. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 10.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,725,979 shares of the biopharmaceutical company’s stock after acquiring an additional 156,952 shares during the period. Jupiter Asset Management Ltd.’s holdings in Pfizer were worth $41,838,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer during the 1st quarter valued at $27,000. Curio Wealth LLC boosted its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new position in shares of Pfizer during the first quarter valued at about $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer in the second quarter worth about $29,000. Finally, WPG Advisers LLC bought a new stake in shares of Pfizer in the 1st quarter valued at about $35,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.49 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The stock has a market capitalization of $144.93 billion, a P/E ratio of 13.56, a P/E/G ratio of 0.81 and a beta of 0.54. The company’s 50-day moving average is $24.75 and its 200 day moving average is $24.41. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on PFE shares. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.18.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.